The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03800914




Registration number
NCT03800914
Ethics application status
Date submitted
9/01/2019
Date registered
11/01/2019
Date last updated
19/10/2023

Titles & IDs
Public title
High Intensity Interval Training in Fibrotic Interstitial Lung Disease
Scientific title
High Intensity Interval Training in Fibrotic Interstitial Lung Disease: a Randomized Controlled Trial
Secondary ID [1] 0 0
LTU HIIT in ILD
Universal Trial Number (UTN)
Trial acronym
HIIT in fILD
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Fibrotic Interstitial Lung Disease 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - High intensity interval training
Other interventions - Traditional pulmonary rehabilitation

Experimental: High Intensity Interval Training - Participants will undergo a twice-weekly supervised exercise training program for eight weeks. Each session will involve 36 minutes of interval aerobic exercise on a cycle ergometer alternating every 30 seconds between 100% of peak work rate, achieved on the cardiopulmonary exercise test (CPET), plus upper and lower resistance training.

Active Comparator: Traditional pulmonary rehabilitation - Participants will undergo a twice-weekly supervised exercise training program for eight weeks. Each session will involve 30 minutes of continuous aerobic exercise on a cycle ergometer at 60% of the peak work rate achieved on the CPET, plus upper and lower resistance training.


Other interventions: High intensity interval training
36 minutes of interval exercise on cycle ergometer alternating every 30 seconds between 100% peak work rate achieved on cardiopulmonary exercise test and unloaded cycling

Other interventions: Traditional pulmonary rehabilitation
30 minutes of continuous exercise on cycle ergometer at 60% peak work rate achieved on cardiopulmonary exercise test.

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change in endurance time
Timepoint [1] 0 0
Baseline, nine weeks and 6 months following intervention
Secondary outcome [1] 0 0
Change in dyspnea measured using the Dyspnea-12 questionnaire
Timepoint [1] 0 0
Baseline, nine weeks and 6 months following intervention
Secondary outcome [2] 0 0
Changes in fatigue evaluated by the Fatigue Severity Scale
Timepoint [2] 0 0
Baseline, nine weeks and 6 months following intervention
Secondary outcome [3] 0 0
Change in health related quality of life using the St George's Respiratory Questionnaire idiopathic pulmonary fibrosis specific version (SGRQ-I)
Timepoint [3] 0 0
Baseline, nine weeks and 6 months following intervention
Secondary outcome [4] 0 0
Change in health related quality of life using the chronic respiratory disease questionnaire (CRQ)
Timepoint [4] 0 0
Baseline, nine weeks and 6 months following intervention
Secondary outcome [5] 0 0
Change in anxiety and depression measured by the Hospital Anxiety and Depression Scale
Timepoint [5] 0 0
Baseline, nine weeks and 6 months following intervention
Secondary outcome [6] 0 0
Change in functional exercise capacity assessed by 6-minute walk distance
Timepoint [6] 0 0
Baseline, nine weeks and 6 months following intervention
Secondary outcome [7] 0 0
Changes in skeletal muscle size
Timepoint [7] 0 0
Baseline, nine weeks and 6 months following intervention
Secondary outcome [8] 0 0
Dyspnea related disability - measured with modified medical research council scale (MMRC)
Timepoint [8] 0 0
Baseline, nine weeks and 6 months following intervention
Secondary outcome [9] 0 0
Global rating of change
Timepoint [9] 0 0
Baseline, nine weeks and 6 months following intervention
Secondary outcome [10] 0 0
Change in physical activity
Timepoint [10] 0 0
Baseline, nine weeks and 6 months following intervention

Eligibility
Key inclusion criteria
- Diagnosis of fibrotic interstitial lung disease (fILD)

- Able to read and speak English
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Resting oxygen saturation (SpO2) is < 85%

- Severe pulmonary hypertension (WHO class IV)

- Attendance at Pulmonary rehabilitation (PR) within last 12 months

- Comorbidities which preclude exercise training

- History of syncope on exertion

- Significant cognitive impairment

- Anticipated transplant or death within the duration of the study period

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Sydney
Recruitment hospital [2] 0 0
Prince Charles Hospital - Brisbane
Recruitment hospital [3] 0 0
Austin Health - Heidelberg
Recruitment hospital [4] 0 0
Alfred Health - Melbourne
Recruitment postcode(s) [1] 0 0
2050 - Sydney
Recruitment postcode(s) [2] 0 0
4032 - Brisbane
Recruitment postcode(s) [3] 0 0
3084 - Heidelberg
Recruitment postcode(s) [4] 0 0
3004 - Melbourne

Funding & Sponsors
Primary sponsor type
Other
Name
Monash University
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The fibrotic interstitial lung diseases (fILD) is a group of debilitating chronic lung
conditions that are characterised by scarring of lung tissue, dyspnoea on exertion and
significant physical impairment. Exercise training is recommended for people with fILD in
improving breathlessness and exercise tolerance. However, despite the best efforts of
patients and clinicians, many of those who participate are not attaining its benefits. The
current exercise training strategies of moderate intensity continuous training may not be
well suited to fILD. High intensity interval training (HIIT), short bouts of high-intensity
exercise regularly interspersed with periods of rest or light exercise may be an alternate
exercise training option for people with fILD.

The study will determine to whether HIIT is better than the current method of continuous
exercise training at moderate intensity in improving exercise tolerance, breathlessness and
quality of life in people with fILD. A randomised controlled, assessor blinded trial will be
conducted. A total 130 people with fILD will be randomly assigned to moderate intensity
continuous training or HIIT. If this trial demonstrates that HIIT is effective, it will
provide an exercise training strategy that can readily be implemented in practice that will
maximise the outcomes of exercise training for people with fILD.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03800914
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Anne Holland
Address 0 0
Monash University
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Anne Holland
Address 0 0
Country 0 0
Phone 0 0
+61 3 99030214
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03800914